Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 30
- Registration Number
- NCT02859766
- Locations
- 🇺🇸
Atlantis Retina Institute (Atlantis Eyecare), Huntington Beach, California, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Jacobs Retina Center, Shiley Eye Institute, UCSD, La Jolla, California, United States
Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia
- Conditions
- Interventions
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 11
- Registration Number
- NCT02848300
- Locations
- 🇺🇸
DermResearch, LLC, Austin, Texas, United States
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
- Conditions
- Interventions
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Allergan
- Target Recruit Count
- 834
- Registration Number
- NCT02848326
- Locations
- 🇺🇸
Central Texas Neurology Consultant, Round Rock, Texas, United States
🇺🇸Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸iResearch Atlanta, LLC, Decatur, Georgia, United States
A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 221
- Registration Number
- NCT02833077
- Locations
- 🇺🇸
Skin Research Institute, Coral Gables, Florida, United States
🇺🇸Baumann Cosmetic and Res. Institute, Miami Beach, Florida, United States
🇺🇸SkinCare Physicians of Chestnut Hill, Chestnut Hill, Massachusetts, United States
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1672
- Registration Number
- NCT02828020
- Locations
- 🇺🇸
Prime Care Clinical Research, Laguna Hills, California, United States
🇺🇸Medical Center for Clinical Research, San Diego, California, United States
🇺🇸Clinical Research Advantage, Inc./Diagnostic Center of Medicine - Durango, Las Vegas, Nevada, United States
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 36
- Registration Number
- NCT02815293
- Locations
- 🇺🇸
Eye Doctors of Washington, Chevy Chase, Maryland, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
🇺🇸Eye Care Centers Management, Inc. dba Clayton Eye Center, Morrow, Georgia, United States
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 169
- Registration Number
- NCT02781311
- Locations
- 🇺🇸
DeNova Research, Chicago, Illinois, United States
🇺🇸Cleveland Clinic, Dept of Dermatology, Cleveland, Ohio, United States
🇺🇸Heartland Research Associates, LLC, Wichita, Kansas, United States
A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Allergan
- Target Recruit Count
- 151
- Registration Number
- NCT02780115
- Locations
- 🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸Wolstan and Golberg Eye Associates, Torrance, California, United States
🇺🇸MedEye Associates, Miami, Florida, United States
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 202
- Registration Number
- NCT02731911
- Locations
- 🇦🇺
Retina and Macula Specialists,Hurstville, Hurtsville, New South Wales, Australia
🇦🇺Retina Associates, Liverpool, New South Wales, Australia
🇦🇺Retina and Macula Specialists, Miranda, Miranda, New South Wales, Australia
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 53
- Registration Number
- NCT02676310
- Locations
- 🇺🇸
J&S Studies Inc., College Station, Texas, United States
🇺🇸E&R Research Foundation, Lynchburg, Virginia, United States
🇺🇸DermResearch, LLC, Austin, Texas, United States